Remedy Pharmaceuticals has announced that three speaker presentations reporting efficacy data from both the Phase 2 GAMES-RP and Phase 3 CHARM studies on its stroke drug, Cirara (intravenous glyburide), will be given at the upcoming International Stroke Conference (ISC; 5–7 February, Los Angeles, USA).
A company press release notes that these presentations will focus on efficacy results from the GAMES-RP and CHARM studies, and their implications for improving outcomes in patients with large hemispheric infarction (LHI).
One presentation—scheduled for the morning of day one at ISC 2025—will feature a meta-analysis evaluating Cirara’s efficacy in treating LHIs with core lesion volumes of 125mL or smaller by combining data from the GAMES-RP and CHARM trials. The presentation will be delivered by W Taylor Kimberly (Massachusetts General Hospital/Harvard Medical School, Boston, USA), co-principal investigator for the two studies.
Later during the same day, Kevin Sheth (Yale School of Medicine, New Haven, USA)—also co-principal investigator on the GAMES-RP and CHARM studies—will present an analysis examining Cirara’s potential to improve outcomes in LHI patients treated with endovascular therapy (EVT) within the CHARM trial.
Sheth will return to the podium on the afternoon of day two at ISC 2025 to deliver a presentation on the long-term outcomes of the CHARM trial, highlighting six- and 12-month results with Cirara in the treatment of LHI.
“These analyses from the CHARM and GAMES-RP trials represent a pivotal opportunity to advance the treatment landscape for large hemispheric infarction,” said Sven Jacobson, chief executive officer (CEO) of Remedy Pharmaceuticals. “The presentations at ISC 2025 highlight the robust efficacy of Cirara and reinforce our commitment to improving outcomes for patients with this devastating condition.”
